Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance and Biotransformation of [14C]-Fluzoparib in Solid Tumors
NCT04013048Phase 1Completed
- Sponsor
- Hengrui
- Start
- Jul 2019
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fluzoparib in solid tumor, sponsored by Hengrui. Primary endpoints: Distribution of Fluzoparib in whole blood and plasma and whole radioactive pharmacokinetics up to 10 days, Mass balance and main excretion pathway up to 10 days and 3 more. Started Jul 2019; status: completed.
02
Drugs
fluzoparib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04013048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04013048.